All In MedTech

FDA Clearance Tracker · P980035

MEDTRONIC KAPPA 700/600 SERIES PULSE GENERATORS AND MODEL 9953 SOFTWARE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jan 29, 1999 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jan 29, 1999

Approved

Time to decision

157 days

Received Aug 25, 1998. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P980035
Device name
MEDTRONIC KAPPA 700/600 SERIES PULSE GENERATORS AND MODEL 9953 SOFTWARE
Applicant location
Mounds View, MN
Received
Aug 25, 1998
Decided
Jan 29, 1999
Decision
Approved
Supplements
823 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NVZ

FDA's approval statement

As written in FDA's record.

Approval for the Medtronic.Kappa(TM) 700/600 Series Pacemakers, which include; Medtronic.Kappa(TM) Kdr 701, 703, 706, 721, 731, 733, 601, 603, and 606; Kd 701, 703, and 706; Kvdd 701; and Ksr 701, 703, and 706 implantable pacemakers with Medtronic.Vision (Model 9953E) Software. These devices are indicated for the following: Rate adaptive pacing in patients who may benefit from increase pacing rates concurrent with increases in activity; Accepted patient conditions warranting chronic cardiac pacing which include: - Symptomatic parosysmal or permanents second or third-degree AV block; - Symptomatic bilateral bundle branch block; - Symptomatic paroxysmal or transient sinus node dysfunctions with or without assocated AV conduction disorders; - Bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; - Vasovagal syndromes or hypersensitive carotid sinus syndromes. In addition, Medtronic.Kappa(TM) 700/600 Series pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include: -various degrees of AV block to maintain the atrial contribution to cardiac output; -VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm. Medtronic.Kappa(TM) 700/600 Series pacemakers are also indicated for VDD modes in patients having adequate atrial rates and the following indications: - Requirements for ventricular pacing when adequate atrial rates and adequate intracavitary atrial complexes are present. This includes the presence of complete AV block when atrial contribution is needed for hemodynamic benefit or when pacemaker syndrome has existed or is anticipated. Normal sinus rhythm and normal AV conduction in patients needing ventricular pacing intermittently.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NVZ. The earliest in FDA's data is P890003, decided Aug 24, 1989.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.